Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Hepatic Tumor Ablation
NCT07034950Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esketamine in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Xiamen University. Started Jun 2025; status: active, not recruiting.
02
Drugs
esketamine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07034950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034950.